Zhen Xu, Ph.D., professor, Michigan Medicine
Rogel member Zhen Xu, Ph.D., was selected to Time magazine’s TIME100 Health. The magazine describes it as a list of the “the people most influential in the world of health right now.”
Time’s health reporters consulted with experts around the world to identify scientists, doctors, advocates, educators and policy-makers “who are changing the health of the world.”
Xu was recognized for developing histotripsy, which was approved by the U.S. Food and Drug Administration in 2023 to treat liver tumors.
Read more: https://time.com/collections/time100-health-2026/7362509/zhen-xu/
Media Contact
Public Relations
Department of Communication at Michigan Medicine
In This Story
Zhen Xu
Professor
Related
Health Lab
Histotripsy stimulates the immune system to attack cancer cells outside the liver
The University of Michigan Health pioneered the treatment histotripsy for liver cancer, which is helping teach the immune system which cancer cells to attack.
Health Lab
Histotripsy can help release HER2 from cancer tumor cells
A study demonstrates how histotripsy could stimulate the immune system to destroy a cancer through the release of tumor antigens.
Featured News & Stories
Philanthropy News
Long friendship inspires urology resident fund
U-M alumni Stephen and Faith Brown have created a fund to expand research and travel opportunities for urology residents in the U-M Medical School.
Health Lab
Researchers create new path to target hard-to-drug prostate cancer protein
University of Michigan researchers have identified a specific pocket within ERG, a driver of prostate cancer, and have developed a small molecule probe, called PBITE-1, that can bind to it.
Philanthropy News
Gifts advance colon cancer prevention and early detection
The Rose and Lawrence C. Page, Sr. Family Charitable Foundation supports lifesaving colon cancer research at Michigan Medicine.
Health Lab
Study explains how colorectal cancer cells maintain high iron levels
How colorectal cancer cells maintain high iron levels, according to Michigan Medicine research.
Health Lab
Receiving personalized treatment for a rare neuroendocrine tumor
Danielle Schuldt was diagnosed with a rare endocrine tumor and underwent surgery as part of her treatment. She now undergoes regular surveillance to monitor for cancer recurrence.
Health Lab
Phase 1 trial of alrizomadlin shows promise in targeting metastatic salivary gland cancers
University of Michigan researchers, in partnership with Ascentage Pharma, developed a drug known as alrizomadlin, or APG-115, to target metastatic salivary gland cancers.
